Transcribe your podcast
[00:00:00]

Everyone, Dr.

[00:00:01]

David Hill here with my good friend, Dr.

[00:00:03]

Russell Laska Thorpe.

[00:00:05]

Russell, welcome.Thank you.

[00:00:06]

Nice to have you here.

[00:00:07]

I'd like to take a momentjust to introduce herself.

[00:00:10]

Sure you are.My name is Dr.

[00:00:11]

Oz Thorpe.You can call me Dr.

[00:00:13]

.

[00:00:13]

I'm a pediatric infectious disease doctor,and I'm really glad to be at Doctora.

[00:00:17]

Well, we're happy to have you here.

[00:00:19]

And today we're going to talka little bit about Capalaba and CBD.

[00:00:23]

I would like to put it into a contextof four very specific things.

[00:00:27]

And this is going to surprise you.

[00:00:28]

But price purity.

[00:00:31]

Yeah, potency.

[00:00:33]

And then I'd also like to talk about somenew discovery we're making for pathway.

[00:00:37]

Yeah.

[00:00:37]

And I want to relate those allto CBD and this comparison to fiber.

[00:00:42]

And one of the things that we know about

[00:00:43]

CBD is that everybody has hadseemingly great experience.

[00:00:48]

We know that there's a good amountof information that's available and we

[00:00:51]

don't want to bediscounting of any of that.

[00:00:53]

So let's just talk somevery specific things.

[00:00:56]

When you think of those first threethings, price, potency and purity,

[00:01:00]

what comes to mind to youin the marketplace today?

[00:01:04]

CBD is flooded all over the place.

[00:01:07]

It's in every product imaginable,

[00:01:09]

from mascara to doggie treatsand everything in between.

[00:01:12]

The trouble is that when people are taking

[00:01:14]

it to help them with problems that theyhave with their health,

[00:01:19]

the doses that are required are so highthat the price point is really painful.

[00:01:23]

Well, it becomes painful and becomesunobtainable for most people.

[00:01:27]

And purity is a different animal for me.

[00:01:29]

I'm going to drill themon this just a little bit.

[00:01:31]

It's still Tear's calling it.

[00:01:32]

It's it's what we do.It's what we know.

[00:01:35]

And I know the intensitythat goes with that.

[00:01:36]

And in an industry that, as you indicated,has this plethora of products,

[00:01:41]

we see a lot of inconsistencies in termsof the amount that's available of the CBD,

[00:01:47]

where some of the differencethat you see that.

[00:01:48]

Well, the trouble with CBD is

[00:01:52]

that the hemp industry where CBD comesfrom is not very regulated

[00:01:57]

and the products that are madeare not checked for purity.

[00:02:01]

And the amount of CBD within those

[00:02:04]

products can be highly variablebecause of the dissonance that exists

[00:02:09]

between the federal and statestatutes around CBD.

[00:02:12]

Right.

[00:02:13]

It's not a good time for us asa company to enter that arena.

[00:02:17]

Let's look at the Indo cannabinoid systemCB1 CB2 receptors.

[00:02:23]

Join me to explain it really quickly.

[00:02:24]

A very quick for everybody to understand

[00:02:26]

so that the endocannabinoid system in ourbody controls a whole host of things.

[00:02:30]

Eat, sleep, forget, relax,

[00:02:32]

and the receptor tone matters and youchange that receptor tone by these

[00:02:37]

chemicals that our bodymakes for ourselves.

[00:02:39]

We call them endocannabinoids.

[00:02:41]

In the plant world.

[00:02:42]

There are lots of chemicals that plants

[00:02:44]

make that interact with ourown body's receptors.

[00:02:47]

They call they're calledphyto cannabinoids.

[00:02:49]

And CBD is one of thosebeta carotene as another.

[00:02:53]

Right.And that potency issue,

[00:02:55]

how much power you get to that system,either up regulating or down regulating

[00:03:00]

that system depends on howyou bind to those receptors.

[00:03:04]

And beta karrar offline isa direct binder to the system.

[00:03:07]

Correct.And CBD is an indirect binder.

[00:03:10]

So this offers some explanation whywe're not saying that CBD has no value.

[00:03:16]

It's just a different circumstance.

[00:03:18]

Correct, in the amount that we havepresent within those two products.

[00:03:21]

By comparison,when we look at Captivities Santoya,

[00:03:24]

when we look at CBD,they're very different,

[00:03:26]

they're very different,and we really don't compare them.

[00:03:29]

And this is one of the thingsthat I've become most excited about

[00:03:32]

with Kaposvar is that the beta carotene,this phyto cannabinoid that you talked

[00:03:37]

about, that in and of itselfresides in substantial amounts.

[00:03:42]

There's really little question about arewe getting some efficacious dosages

[00:03:47]

associated with that? The potency that youcan obtain by getting a purified product

[00:03:51]

from Capalaba with bettercare of is quite high.

[00:03:54]

I really get excited about what we'recurrently discovering with Path Pathway.

[00:03:59]

And so let's talk about that,because you've already indicated that one

[00:04:03]

of the differences that we see as weactivate this system and we're talking

[00:04:08]

about CB2 receptors,we have indirect consequence and direct

[00:04:12]

consequence in the downstream effect thatboth of those create that we're after.

[00:04:17]

So binding at the receptorlevel is really important.

[00:04:20]

But what matters in the cell is how youget to your end result, which is changing

[00:04:27]

DNA, proteins, enzymes,the cellular functions

[00:04:32]

and direct binding at these receptors haseffects that will drive cellular

[00:04:39]

mechanisms to change certainoutcomes within the body.

[00:04:42]

One of the other things that I have liked

[00:04:44]

about Capalaba as an essential oilproduct is the diversity that we see.

[00:04:49]

It's not just Feydeaucannabinoid that's there.

[00:04:52]

It's not just the Medicare Offaly.

[00:04:54]

We have lots of other chemistryand that provides some diversity for us.

[00:04:58]

And so unlike.

[00:04:59]

The CBD, when we look at Capalaba as

[00:05:02]

an essential oil,we have potential for other benefits

[00:05:05]

that really can even resideoutside of the endocannabinoids.

[00:05:09]

When we when we talk about Capalaba, we'renot just talking about Baedeker offline.

[00:05:13]

I agree.

[00:05:14]

There are many molecules withinthe essential oil,

[00:05:17]

many of which have plant chemistry behindthem, where we know that there are going

[00:05:22]

to be other effects than just simply theendocannabinoid system, Baedeker offline.

[00:05:27]

However, being a major component,and that's one of the things that we love

[00:05:30]

about it, is that we'reconfident we have potency.

[00:05:33]

We know that we have purity and we know

[00:05:35]

that it's directed to thecannabinoid system.

[00:05:40]

I've seen a bottle of CBD

[00:05:43]

sometimes sell for hundreds of dollars.Sure.

[00:05:46]

And the amount that I would have

[00:05:47]

to consume based on the discussionthat we've had is exponentially higher

[00:05:52]

than what we would see with something likeCapalaba that has higher chemistry,

[00:05:57]

certainly not hundredsof dollars a bottle.

[00:05:59]

And we've also know and have lookedat the research and know

[00:06:02]

that by comparison we can have very smalldosage amounts and still create

[00:06:07]

the benefit in the effectthat we're looking for.

[00:06:09]

That, to me, is oneof the critical things.

[00:06:11]

I get greater benefit from theco-payment and higher value.

[00:06:14]

I get greater efficacy and Ihave much higher value.

[00:06:17]

I come back to as well those four P's.

[00:06:19]

I think it's the foundationof what DR does.

[00:06:24]

Purity and price are extremely important

[00:06:26]

when you're talking abouta product like this.

[00:06:28]

And I think that Capalaba will

[00:06:30]

define itself in the marketplacequite nicely over time.